Tags

Type your tag names separated by a space and hit enter

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
PLoS One. 2011 Jan 31; 6(1):e16496.Plos

Abstract

BACKGROUND

The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. (clinicaltrials.gov Identifier:NCT01066169).

METHODS AND FINDINGS

In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21). Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The seroprotection rate (defined as HI titers ≥ 1 : 40) for HIV-infected patients was 88% after the first and 91% after the second vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%). Seroprotective titers at baseline were much more common in those who had received 2009-2010 seasonal TIV three weeks prior to the first dose of pH1N1 vaccine. Using stored serum samples of 51 HIV-infected participants we measured the pH1N1 specific response to 2009-2010 seasonal TIV. The seroprotection rate to pH1N1 increased from 22% to 49% after vaccination with 2009-2010 seasonal TIV. Seasonal TIV induced higher levels of antibodies to pH1N1 in older than in younger subjects.

CONCLUSION

In HIV-infected patients on combination antiretroviral therapy, with a median CD4+ T-lymphocyte count above 500 cells/mm(3), one dose of MF59-adjuvanted pH1N1 vaccine induced a high seroprotection rate comparable to that in healthy controls. A second dose had a modest additional effect. Furthermore, seasonal TIV induced cross-reactive antibodies to pH1N1 and this effect was more pronounced in older subjects.

Authors+Show Affiliations

Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. d.soonawala@lumc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21304982

Citation

Soonawala, Darius, et al. "Response to 2009 Pandemic Influenza a (H1N1) Vaccine in HIV-infected Patients and the Influence of Prior Seasonal Influenza Vaccination." PloS One, vol. 6, no. 1, 2011, pp. e16496.
Soonawala D, Rimmelzwaan GF, Gelinck LB, et al. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6(1):e16496.
Soonawala, D., Rimmelzwaan, G. F., Gelinck, L. B., Visser, L. G., & Kroon, F. P. (2011). Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PloS One, 6(1), e16496. https://doi.org/10.1371/journal.pone.0016496
Soonawala D, et al. Response to 2009 Pandemic Influenza a (H1N1) Vaccine in HIV-infected Patients and the Influence of Prior Seasonal Influenza Vaccination. PLoS One. 2011 Jan 31;6(1):e16496. PubMed PMID: 21304982.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. AU - Soonawala,Darius, AU - Rimmelzwaan,Guus F, AU - Gelinck,Luc B S, AU - Visser,Leo G, AU - Kroon,Frank P, Y1 - 2011/01/31/ PY - 2010/10/08/received PY - 2010/12/20/accepted PY - 2011/2/10/entrez PY - 2011/2/10/pubmed PY - 2011/8/4/medline SP - e16496 EP - e16496 JF - PloS one JO - PLoS One VL - 6 IS - 1 N2 - BACKGROUND: The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. (clinicaltrials.gov Identifier:NCT01066169). METHODS AND FINDINGS: In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21). Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The seroprotection rate (defined as HI titers ≥ 1 : 40) for HIV-infected patients was 88% after the first and 91% after the second vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%). Seroprotective titers at baseline were much more common in those who had received 2009-2010 seasonal TIV three weeks prior to the first dose of pH1N1 vaccine. Using stored serum samples of 51 HIV-infected participants we measured the pH1N1 specific response to 2009-2010 seasonal TIV. The seroprotection rate to pH1N1 increased from 22% to 49% after vaccination with 2009-2010 seasonal TIV. Seasonal TIV induced higher levels of antibodies to pH1N1 in older than in younger subjects. CONCLUSION: In HIV-infected patients on combination antiretroviral therapy, with a median CD4+ T-lymphocyte count above 500 cells/mm(3), one dose of MF59-adjuvanted pH1N1 vaccine induced a high seroprotection rate comparable to that in healthy controls. A second dose had a modest additional effect. Furthermore, seasonal TIV induced cross-reactive antibodies to pH1N1 and this effect was more pronounced in older subjects. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/21304982/Response_to_2009_pandemic_influenza_A__H1N1__vaccine_in_HIV_infected_patients_and_the_influence_of_prior_seasonal_influenza_vaccination_ L2 - https://dx.plos.org/10.1371/journal.pone.0016496 DB - PRIME DP - Unbound Medicine ER -